Ziconotide: An update and review

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 9, 2008, Pages 1575-1583

  Williams, Jason A ^a   Day, Miles ^a   Heavner, James E ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Chronic pain; Intrathecal infusion; N type calcium channel blocker; Ziconotide

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; BACLOFEN; BUPIVACAINE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; CARBAMAZEPINE; CHOLINERGIC RECEPTOR; CLONIDINE; DANTROLENE; DIAZEPAM; DIURETIC AGENT; HYDROMORPHONE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT; NMED 160; OMEGA CONOTOXIN MVIIA; PLACEBO; SEDATIVE AGENT; OMEGA CONOTOXIN;

ALLODYNIA; AMNESIA; ANALGESIC ACTIVITY; ANAPHYLAXIS; ANTINOCICEPTION; ASTHENIA; ATAXIA; BLURRED VISION; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CONFUSION; CONTINUOUS INFUSION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG CROSS TOLERANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GAIT DISORDER; HUMAN; HYPERALGESIA; HYPERTENSION; INFORMATION RETRIEVAL; INSOMNIA; MEDLINE; MEMORY DISORDER; NAUSEA; NEURALGIA; NEUROPATHIC PAIN; NONHUMAN; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; PAIN; PATIENT CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOMNOLENCE; SPASTICITY; SPINAL ANESTHESIA; SYSTEMIC THERAPY; THORAX PAIN; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING; ANIMAL; DRUG COMBINATION; DRUG INTERACTION; INTRASPINAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, SPINAL; OMEGA-CONOTOXINS; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 46749141315     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.9.1575     Document Type: Review

References (27)

1. Turner JA, Sears JM, Loeser JD. Programmable intrathecal opioid delivery systems for chronic no cancer pain: a systematic review of effectiveness and complications. Clin J Pain 2007;23:180-95
2. Williams JE, Louw G, Towlerton G. Intrathecal pumps for giving opioids in chronic pain: a systematic review. Health Technol Assess 2000;4:1-65
3. Hassenbusch SJ, Portenoy RK, Cousins M, et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery - report of an expert panel. J Pain Symptom Manage 2004;27:540-63
4. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary panel. Neuromodulation 2007;10:300-28
5. Koltz U. Ziconotide - a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain a short review. Int J Clin Pharm Ther 2006;44:478-83
6. Available from: http://www.portfolio.mvm.ed.ac.uk/studentwebs/session2/ group13/snails.html.
7. Olivera BM, Teichert RW: Diversity of the neurotoxic peptides. Mol Intervent 2007;7:251-60
8. Product information. ziconotide. In: investigator's Brochure. San Diego CA: Elan Pharmaceuticals, Inc.; 2004
9. Wermeling DP. Ziconotide, an intrathecally administered N-type calcium channel antagonist for the treatment of chronic pain. Pharmacotherapy 2005;25:1084-94
10. Prommer EE. Ziconotide: can we use it in palliative care? Am J Hospice Palliat Med 2005;22:369-74
11. Wallace MS. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother 2006;6:1423-8
12. Available from: http://www.thomsonhc.com/hcs/librarian/PFPUI/ TP1mNbz2nkQ9Rn (Micromedex Healthcare Series through Texas Tech University HSC library: keyword ziconotide)
13. Available from: http://www.pbm.va.gov/DrugMonograph.aspx
14. Webster LR, Fakata KL< Charapata S, et al. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med 2008;9:282-90
15. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine and hydromorphone during simulated intrathecal administration. Neuromodulation 2005;8:257-63
16. Shields D, Montenegro R, Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):1-5
17. Shields D, Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixture with and without morphine sulfate during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):6-11
18. Shields D, Montenegro R< Aclan J. Chemical stability of an admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation 2007;10(Suppl 1):12-17
19. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004;291:63-70
20. Atanassoff PG, Hartmannsgruber MW, Thrasher J, et al. Ziconotide, a new n-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med 2000;25:274-8
21. Ridgeway B, Wallace MS, Gerayli A. Ziconotide for the treatment of severe spasticity after spinal cord injury. Pain 2000;85:287-9
22. Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006;31:393-406
23. Wallace MS, Kosek PS, Staats P, et al. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008;9:271-281
24. Stanton-Hicks M, Kapural L. An effective treatment of severe complex regional pain syndrome type I in a child using high doses of intrathecal ziconotide. J Pain Symptom Manage 2006;32:509-11
25. Wermeling DP, Berger JR. Ziconotide infusion for severe chronic pain: case series of patients with neuropathic pain. Pharmacotherapy 2006;26:396-402
26. Mcguire D, Bowersox S, Fellman JD, et al. Sympatholysis after neuron-specific, n-type, voltage-sensitive calcium channel blockade: first demonstration of n-channel function in humans. J Cardiovasc Pharmacol 1997;30:400-3
27. Available from: http://www.neuromed.com/news/ pressr.php?nr=15&txt=&pyear=2006